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ABSTRACT 
 
Sepsis is a hard to define condition associated with the deleterious systemic inflammatory 
response syndrome (SIRS) which ultimately leads to the failure of multiple organs. The 
mediators released throughout this exaggerated inflammatory reaction activate 
coagulation pathways and generate a dysfunctional response that results in coagulopathy.  
The present dissertation includes a literature review regarding the subject of sepsis and 
associated coagulopathy, along with a study that primarily aims to investigate the use of 
abnormal coagulation times as biological markers of coagulation dysfunction and as 
predictors of outcome in veterinary patients who are at risk of developing sepsis.   
The results suggest that pairing coagulation time data with an organ failure scoring system 
may be advantageous in the prediction of outcome. Furthermore, critically ill patients 
should be given a five-day time frame following admission before euthanasia is 
considered, as most tend to survive their illnesses once they get past this period. 
 
Keywords: Sepsis; Coagulation; SIRS; Emergency; Critical Care 
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RESUMO 
COAGULOPATIA NA SÉPSIS E O VALOR DE PROGNÓSTICO DE 
TEMPOS DE COAGULAÇÃO ALTERADOS 
 
A sépsis é uma síndrome de difícil definição e que está associada à síndrome da resposta 
inflamatória sistémica (SIRS) que leva à falha de múltiplos órgãos. Os mediadores 
libertados durante esta reação inflamatória exagerada levam à ativação disfuncional da 
coagulação sanguínea, o que resulta em coagulopatia. 
A presente dissertação inclui uma revisão bibliográfica sobre o tema da sépsis e a 
coagulopatia associada, bem como um estudo cujo objetivo primário é o de investigar a 
utilização de tempos de coagulação alterados, tanto como marcadores biológicos de 
disfunção da coagulação sanguínea bem como fatores de prognóstico em pacientes 
veterinários em risco de sépsis. 
Os resultados do estudo realizado mostram vantagem em associar a avaliação dos tempos 
de coagulação com sistemas de pontuação de falha orgânica para a realização do 
prognóstico. Estes sugerem também que os pacientes críticos que ultrapassam os 
primeiros cinco dias após a sua admissão hospitalar tendem a sobreviver.  
 
Palavras-chave: Sépsis; Coagulação; SIRS; Urgências; Cuidados Intensivos 
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PREFACE 
 
The present dissertation was written following a six-month internship, from September 
2016 to March 2017, at Hospital Veterinário da Arrábida and Centro de Reabilitação 
Animal da Arrábida, a small animal hospital connected to a referral rehabilitation centre 
in the civil parish of Azeitão in Portugal. 
Many areas of veterinary medicine were explored throughout this internship, including 
diagnostics, emergency and critical care medicine, orthopaedic and soft tissue surgery, 
internal medicine, and small animal rehabilitation. It was during this period that the author 
determined the topic of his research and began collecting the data that would be 
subsequently analysed, after developing a particular interest in the subject of sepsis in 
critically ill patients. 
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1. LITERATURE REVIEW 
 
1.1. INTRODUCTION TO THE DEFINITION OF SEPSIS 
Defining sepsis is not an easy task. The word “sepsis” is as old as ancient Greece when it 
was originally used to describe decomposition in the presence of bacteria1, long before 
anything was known about this serious condition.2 Prior to 1989, sepsis was merely 
believed to be associated with bacteraemia.3 
In 1989, Bone et al.4 defined sepsis syndrome as “the systemic manifestations of 
presumed sepsis”. However, this definition of a systemic response to infection was based 
on a set of clinical signs which could be found in the absence of infection. This fact led 
to the creation of the concept of a “Systemic Inflammatory Response Syndrome” (SIRS) 
in a consensus conference held by the American College of Chest Physicians and the 
Society of Critical Care Medicine in 1991.5 SIRS was created to describe the 
inflammatory response found in sepsis, regardless of its cause. It was established that 
infection, as well as trauma, pancreatitis, and other non-infectious insults, could trigger 
this response. It was also suggested that the term sepsis should only be used if SIRS was 
the result of a confirmed infectious process. SIRS was associated with variables such as 
altered temperature (hypothermia or hyperthermia), heart rate (bradycardia or 
tachycardia), respiratory rate (bradypnea or tachypnea), and white blood cell count 
(leukocytosis or leukopenia), and would be diagnosed if a human patient was positive for 
at least two of these four criteria.5 It has later been suggested that dogs should also meet 
two of these criteria to be diagnosed with SIRS whereas cats would need to fulfil three 
criteria for the same purpose.6,7 In addition to the definition of SIRS, the notions of 
“severe sepsis” and “septic shock” were introduced to describe different stages of sepsis. 
The concept of a “Multiple Organ Dysfunction Syndrome” (MODS) was also established 
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to describe the presence of altered organ function in an acutely ill patient such that 
homeostasis could not be maintained without intervention.5 
Despite the general acceptance of this new definition of sepsis, many clinicians did not 
fully agree with it.8–10 This new approach did not seem to provide a precise definition of 
sepsis and many considered the SIRS criteria to be too sensitive and nonspecific for its 
diagnosis since a large number of patients admitted to intensive care units would meet 
such criteria and would thus be considered septic.11–16 In 2001, an International Sepsis 
Definitions Conference was held in an attempt to tackle these issues by revisiting the 
previous definitions surrounding sepsis.9 It was recognised that, while still useful, the 
diagnostic criteria for SIRS were overly sensitive and nonspecific. Thus, a list of 
additional signs and symptoms of systemic inflammation in response to infection was 
presented to more accurately reflect the host’s clinical response. However, this list was 
arguably too long to be universally adopted, and the SIRS criteria continued to be used to 
diagnose sepsis.2 A conceptual staging system for sepsis called PIRO, inspired by the 
Classification of Malignant Tumours (TNM) system, was also proposed at this conference 
as a potential tool for sepsis patient stratification. In the PIRO (an acronym for 
Predisposition, Infection, Response and Organ dysfunction) model, P refers to all 
predisposing factors which may impact the outcome of sepsis, such as genetic variability, 
age, the presence of concomitant diseases, and nutritional status. In veterinary patients, 
racial predisposition would fit into this component. I refers to the description of the 
infection, which includes its etiologic agent, location, and extent. R concerns the host’s 
inflammatory response to sepsis. Finally, O corresponds to the number of failing organs 
and the degree of dysfunction. Although promising, PIRO was yet to be fully developed 
and required further investigation.9,17–19 
SIRS criteria continued to be criticised for their inadequacy, and the need for a new 
definition of sepsis remained.20–23 In 2016, the authors of the Third International 
Consensus Definitions for Sepsis and Septic Shock released newly updated definitions 
for sepsis and septic shock. It was suggested that these would be regarded as Sepsis-3, 
while the 1991 and 2001 versions would be known as Sepsis-1 and Sepsis-2, respectively. 
Improved understanding of sepsis pathobiology led to its current definition of a “life-
threatening organ dysfunction caused by a dysregulated host response to infection”.24 
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Furthermore, septic shock was considered a subset of sepsis associated with a higher 
mortality rate and was characterised by the need for vasopressor therapy to maintain the 
mean arterial pressure (MAP) of 65 mmHg or more, as well as the presence of serum 
lactate levels higher than 2 mmol/L despite appropriate fluid resuscitation.25 
To assess organ dysfunction severity and recognise sepsis in critically ill patients with 
suspected infection, the authors of Sepsis-3 suggested the use of the Sequential Organ 
Failure Assessment (SOFA) score. A SOFA score of at least two points is indicative of 
organ dysfunction and is associated with a higher mortality rate when compared with 
lower scores. However, SOFA is rather complex and requires laboratory testing, and 
therefore using it to quickly identify sepsis outside of an intensive care unit (ICU) setting 
is not realistic. To address this issue, the authors of Sepsis-3 proposed the use of a new 
straightforward scoring system called “quick SOFA” (qSOFA). This simplified SOFA 
variant can be used to promptly identify patients with suspected infection who are likely 
of developing poor outcomes. To determine these patients, qSOFA analyses the existence 
of altered mentation, hypotension and tachypnea. Each of these clinical signs represents 
one point, and a score equal to or greater than two points is suggestive of organ 
dysfunction.24,26,27 
Controversy has always surrounded the definition of sepsis, and Sepsis-3 is no exception 
to this as many clinicians are not in full agreement with its foundation.28–31 Many 
clinicians believe that the newly recommended criteria for the identification of sepsis 
require further testing before replacing their antecedents.32–35 Despite the most recent 
approach to the definition of sepsis, the SIRS criteria are still considered to be of great 
utility in the identification of infected patients, as well as any other patients suffering from 
sterile SIRS.24,36–39 Sepsis is a very complex condition, and there is yet to exist a widely 
recognised and gold standard way to identify it.40 
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1.2. THE SYSTEMIC INFLAMMATORY RESPONSE 
SYNDROME (SIRS) 
1.2.1 SIGNS OF SIRS IN VETERINARY PATIENTS 
SIRS is a complex and systemic response to an infectious or non-infectious insult that 
may occur in both human and veterinary patients.41 The concepts of sepsis and SIRS and 
all surrounding discussion were initially concerning the human patient. Studies have been 
conducted in an attempt to adapt the SIRS criteria to veterinary patients and establish 
limits for each criterion.6,7 Table 1 shows the suggested criteria, based on such research. 
 
Table 1. Systemic inflammatory response syndrome (SIRS) criteria for dogs and cats 
(data collected from references 6 and 7).  
Clinical Parameters 
Dogs 
(must meet two criteria) 
Cats 
(must meet three criteria) 
Heart rate (beats/min) >120 < 140 or > 225 
Respiratory rate (breaths/min) > 20 > 40 
Rectal temperature (Cº) < 38.1 or >39.2 < 37.8 or > 39.7 
Leukogram (white blood cells/ µL; % band 
cells) 
<6000 or >16,000; > 3 < 5000 or > 19.500; > 5 
 
The suggested SIRS criteria for cats are slightly different from the ones suggested for 
dogs. Besides tachycardia, low heart rates are also frequently found amongst critically ill 
feline patients and should be considered when applying the SIRS criteria. Furthermore, 
cats must express much higher respiratory rates to be diagnosed with tachypnea, when 
compared to dogs. Interestingly, it is also suggested that cats must satisfy at least three 
criteria for the identification of SIRS.7 Dogs, however, are only required to meet two 
criteria for SIRS to be identified, much like what happens with human patients.6 A study 
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performed by Okano et al.42 suggests that, in canine patients, the prognosis worsens as 
more SIRS criteria are met. In that same study, the results also indicated that some 
alterations in the parameters included in the SIRS criteria might be related to worse 
outcomes when compared to others. Abnormalities in body temperature and white blood 
cell count seemed to be linked to a poorer prognosis and were considered to be the most 
reliable of the four parameters to be evaluated since external stimuli can easily influence 
both respiratory and heart rates. Contrary to these findings, a study by Declue et al.43, 
performed with cats, revealed that the number of satisfied SIRS criteria was not correlated 
with prognosis. The dissonance in the results of reports such as these shows how dogs 
and cats can respond differently to inflammation and sepsis and should not be evaluated 
as being part of the same species. 
Infection, heat stroke, pancreatitis, immune-mediated disease, neoplasia, trauma, and 
burns are the most common causes of SIRS in veterinary patients. Clinical signs of SIRS 
are usually nonspecific and can change depending on the underlying disease process. 
They tend to mimic the manifestations of sepsis and are generally treated similarly.44 It is 
important to mention that dogs and humans tend to display clinical signs of an initial 
hyperdynamic phase of sepsis such as loss of appetite, depression, hyperemic mucous 
membranes, bounding peripheral pulses, tachycardia, tachypnea, and fever. Cats, 
however, rarely manifest this hyperdynamic state. Thus, the clinical signs of sepsis found 
in cats tend to be related to a secondary hypodynamic phase and may include lethargy, 
diffuse abdominal pain, pale mucous membranes, tachypnea, bradycardia, hypotension 
and hypothermia. Cats are also more likely to experience hypotension, hypoglycaemia 
and hyperbilirubinemia than dogs.7,44,45 
Blood cell count alterations, such as neutrophilic leukocytosis, and toxic cytologic 
changes of the neutrophils are common in patients with SIRS, as well as a variety of other 
changes on a biochemical level. Blood glucose levels tend to fluctuate between 
hyperglycaemia in the early phase of inflammation when gluconeogenesis is increased, 
and subsequent hypoglycaemia once glucose levels drop as a result of excessive use. 
Albumin concentration levels are likely to drop secondarily to reduced albumin 
production by the liver, in favour of acute phase proteins. Changes in endothelial 
permeability found in SIRS also lead to plasma protein leakage and consequently loss of 
1. LITERATURE REVIEW 
6 
 
albumin.44 The resulting hypoalbuminemia may cause the development of pulmonary and 
peripheral oedema, which was evident in a study performed with cats suffering from 
sepsis, by Brady et al.7 Liver enzymes, such as alanine aminotransferase and aspartate 
aminotransferase, are inclined to increase in concentration due to changes in perfusion 
and decreased tissue oxygenation. Serum bilirubin may also suffer alterations, usually as 
a result of cholestasis.44 Haemolysis may also be responsible for icterus in cats with sepsis 
considering how common anaemia seems to be present in these patients.7 A study by 
Schaefer et al.46 showed that proteinuria is also present in dogs with SIRS, as a result of 
altered urinary protein excretion due to glomerular and tubular malfunction. 
  
1.2.2. PATHOPHYSIOLOGY OF SIRS 
In ancient Rome, Celsus was the first to introduce the four signs widely used to describe 
an inflammatory response: redness (rubor), swelling (tumor), heat (calor), and pain 
(dolor). Many centuries later, a fifth sign, loss of function (function laesa), was added to 
this list.47,48 These terms characterise the visual changes that occur in a localised 
inflammatory response to tissue damage or infection.49 Local blood vessel dilation and 
increased permeability result in the passage of an additional number of erythrocytes and 
fluids into the damaged area resulting in redness, heat, and swelling. Cells also infiltrate 
into the affected area, and prolonged inflammatory responses may generate deposits of 
connective tissue, further increasing the swelling. Resulting oedema leads to the 
stretching of sensory nerves, which results in pain. Pain is also a consequence of the initial 
tissue damage as well as the resulting inflammatory response itself and the effects of its 
mediators. Loss of mobility in structures such as the joints, due to pain and oedema, and 
replacement of once functional cells with scar tissue are examples of circumstances that 
lead to loss of function.48 
The local hemodynamic changes in the inflammatory response are aimed at defending the 
host and eliminating harmful agents and damaged cells.49 Thus, localised inflammation 
is a physiological protective response, controlled by inflammatory mediators. However, 
overactivation of this inflammatory reaction or loss of its local control may result in the 
exaggerated systemic response we know as SIRS.50 
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SIRS is a dysregulated inflammatory response to injury or microbial invasion. Even 
though this syndrome is an essential part of sepsis when triggered by infectious agents, it 
can also occur in the absence of infection. Regardless of the initial insult, the resulting 
inflammatory response is considered to be fairly similar.51 When infection is the cause of 
SIRS, both gram-negative and gram-positive bacteria, as well as parasitic, fungal, 
protozoan and viral microorganisms, can be responsible for inciting the systemic response 
(Figure 1).52 However, infections caused by gram-negative bacteria seem to be both the 
most prevalent and dangerous, in cases of sepsis.53,54 Escherichia coli is the most 
commonly isolated microorganism in dogs and cats with sepsis.7,55–60 Interestingly, in the 
particular case of sepsis associated with pyothorax, members of the genus Pasteurella 
appear to be more commonly isolated in cats amongst facultative bacteria, whereas 
Escherichia coli continues to be more prevalent in dogs.61,62  
 
 
 
Figure 1. The interrelationship between the systemic inflammatory response syndrome 
(SIRS), infection, and sepsis (reprinted from reference 5 with permission from Elsevier).  
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In human patients, the infectious processes that represent the most common causes of 
sepsis are pneumonia, urinary tract infections, intra-abdominal infections, and 
bacteraemia.63 In dogs, sepsis has been linked with conditions such as septic peritonitis, 
pancreatitis, pneumonia, pyometra, prostatitis, and wound infections.6,57 In our domestic 
felines, sepsis has been associated with conditions including septic peritonitis, 
pneumonia, bacteraemia, endocarditis, pyelonephritis, hepatic abscessation, and 
pyothorax.7,58,59,62  
 
1.2.2.1. PATHOGEN AND TISSUE DAMAGE RECOGNITION 
Mammals, such as humans and their small animal companions, possess an immune 
system with the task of protecting them against the invasion of harmful microorganisms. 
This immune system includes both innate and acquired immunity. While the innate 
immune system represents the first line of host defence against infection, the acquired 
immune system is associated with later phases of pathogen elimination and with the 
development of immunological memory.52 The innate immune system is responsible for 
containing the infection and delivering antigens to local lymph nodes, which results in 
the activation of the acquired immune system and consequent eradication of infection.64 
For an invading microorganism to be able to successfully disseminate and cause sepsis 
and septic shock, both innate and acquired immune defences must be breached.65,66 
The innate immune system includes the activity of many different cells such as 
macrophages, neutrophils, natural killer cells (NK), endothelial and epithelial cells, and 
dendritic cells.52,67,68 These cells can detect the presence of molecular structures 
associated with microbial pathogens and tissue damage, as well as endogenous molecules 
released during cellular injury, through a group of surface proteins named pattern 
recognition receptors (PRRs).67–69 Many of these PRRs have been identified and 
extensively studied, and one of the best-understood families of PRRs is the Toll-like 
receptors (TLRs) family.70,71 
PRRs, such as TLRs, can recognise particular components expressed by microorganisms 
known as pathogen-associated molecular patterns (PAMPs), as well as endogenous 
mediators released during tissue injury and cell death known as “alarmins” or danger-
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associated molecular patterns (DAMPs).66,67,71 Some authors seem to consider that the 
term DAMPs includes both PAMPs and alarmins 69,72, but the previous distinction will 
be the one used in the present dissertation.  
Cell wall components, such as lipopolysaccharide (LPS) expressed by gram-negative 
bacteria (one of the most potent PAMPs), flagellin, and bacterial deoxyribonucleic acid 
(DNA) are some examples of PAMPs, which tend to be closely related to the survival or 
pathogenicity of the invading microorganism.68 Examples of DAMPs include heat shock 
proteins, fibrinogen, hyaluronic acid, and components of the endothelial 
glycocalyx.52,73,74 
The recognition of PAMPs and DAMPs by PRRs results in the activation of the cell 
through a downstream of signalling cascades that culminate in a transcriptional response, 
via the mobilisation of transcription factors such as nuclear factor-kappa B (NF-kB) and 
activator protein 1 (AP-1). This cell activation results in the production and secretion of 
inflammatory mediators like cytokines, chemokines and complement-activating 
products.68,71,75–80 Figure 2 exemplifies this response. 
 
  
  
 
 
 
 
  
 
Figure 2. Recognition of infection or tissue injury by a macrophage (original figure). 
DAMP, Danger-associated molecular pattern; PAMP, pathogen-associated molecular 
pattern; TLR, Toll-like receptor.  
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1.2.2.2. THE HYPERINFLAMMATORY RESPONSE IN SIRS 
Cytokines are small protein mediators of low molecular weight (usually less than 40 kDa) 
that initiate, modulate, and sustain inflammatory interactions.76,78 The main 
proinflammatory cytokines responsible for inducing a systemic inflammatory response 
are those of the tumour necrosis factor (TNF) family and some interleukins (ILs), namely 
tumour necrosis factor alpha (TNFα), interleukin 1 (IL-1), and interleukin 6 (IL-6).68,71,79   
Once released into circulation, these cytokines will signal endothelial cells to upregulate 
adhesion molecules that promote the migration of leukocytes from the microcirculation 
into sites of tissue injury or infection, recruiting them to perform the phagocytosis of 
pathogens and removal of damaged and dead host cells. 81–83 This proinflammatory 
environment leads to the secretion of additional cytokines as well as secondary mediators 
such as nitric oxide (NO), reactive oxygen species (ROS), and lipid factors.64,77,84 Under 
controlled inflammatory responses, this process would ultimately result in the clearance 
of infection and tissue healing.67,80  
During SIRS, there is an overstimulation of immune cells as a response to extremely high 
levels of DAMPs from injured host tissue or PAMPs from invading microorganisms.77 
This leads to an uncontrolled production and secretion of proinflammatory mediators, 
also known as “cytokine storm”, that enter the systemic circulation and travel to organs 
distant to the initial site of tissue damage or infection, resulting in the global activation of 
the inflammatory system.80,85  
The acquired immune system is also involved in the production of cytokines and 
development of SIRS and sepsis.85,86 Antigen-presenting cells, such as monocytes and 
dendritic cells, activate the acquired immune response by interacting with naïve T cells 
and driving them to proliferate and differentiate into T helper (Th) cells. T helper 1 (Th1) 
and T helper 17 (Th17) cells are responsible for producing additional proinflammatory 
cytokines whereas T helper 2 (Th2) cells produce anti-inflammatory cytokines. Shifts in 
the balance between Th1/Th17 and Th2 cells dictate the nature of the immune response.85–
87 Early stages of SIRS have been associated with increased proinflammatory cytokine 
production while anti-inflammatory activity and immune suppression are more 
characteristic of later phases of the syndrome.86 
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The autonomic nervous system (ANS) takes part in the inflammatory response as well. 
Immune cells are capable of producing and secreting neurotransmitters, as well as 
expressing receptors for such mediators, allowing the nervous and immune systems to 
communicate during inflammation.77 Released cytokines also provide the central nervous 
system (CNS) with updated information regarding the ongoing inflammatory response.88 
Vagus nerve stimulation triggered by inflammatory stimuli has been shown to suppress 
inflammation.89,90 Efferent activity in the vagus nerve results in acetylcholine (ACh) 
secretion in organs of the reticuloendothelial system such as the liver, heart, spleen, and 
gastrointestinal tract. Exposure of tissue macrophages to ACh inhibits the release of 
proinflammatory cytokines. This anti-inflammatory mechanism is called the “cholinergic 
anti-inflammatory pathway” and is an important part of the “inflammatory reflex” carried 
out by the nervous system to control acute inflammation.91,92 Failure of mechanisms such 
as these due to CNS dysfunction in SIRS may contribute to the exacerbation of the 
inflammatory response.88 Furthermore, some authors have suggested that the release of 
catecholamines by phagocytes and cells of the sympathetic branch of the ANS, in early 
phases of the syndrome, may amplify the proinflammatory responses of macrophages, 
neutrophils and dendritic cells. However, this subject appears to be controversial and not 
yet fully understood.77,93–95 
The hyperinflammatory response developed in SIRS is further aggravated by the systemic 
activation of the complement system, which results in the generation of large amounts of 
proinflammatory peptides that act as leukocyte chemoattractants, enhance adhesion 
molecule expression, increase vascular permeability, and stimulate cytokine 
production.77,84,96,97 Excessive complement activation has also been previously linked to 
neutrophil dysfunction and increased mortality in cases of severe trauma.98,99 
 
1.2.2.3. THE COMPENSATORY ANTI-INFLAMMATORY 
RESPONSE SYNDROME (CARS)  
Following the recognition of PAMPs and DAMPS, proinflammatory cytokines are not 
the only ones to be released. In fact, anti-inflammatory cytokines, such as interleukin 10 
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(IL-10), and proinflammatory cytokine receptor antagonists are also secreted by immune 
cells in an attempt to control the resulting inflammatory response and prevent it from 
becoming excessive and causing damage.100,101 In SIRS, however, this regulatory 
mechanism is overwhelmed, and the development of the exaggerated proinflammatory 
response takes place.49,102 Following the systemic inflammation generated in SIRS, an 
opposing exaggerated anti-inflammatory response may also develop, leading the 
organism to a state of “immune paralysis” and to what is known as the compensatory anti-
inflammatory response syndrome (CARS).102–106 Many patients that survive the initial 
hyperinflammatory phase of SIRS may later succumb to the effects of this status of 
immunological depression.107,108   
There is a large number of phenomena that contribute to the development of CARS, but 
like many other topics surrounding SIRS and sepsis, a great deal of them are still under 
research.104–106,109 One of the hallmarks of CARS is the depletion of many types of 
immune cells via dysregulated apoptosis induced by mediators such as TNFα, IL-1, IL-
6, NO and ROS.66,110–114 An adjusted version of this interaction would represent a 
regulatory mechanism to mediate inflammatory responses. Following SIRS, however, it 
ends up resulting in the death of a lot of immune cells, rendering the organism unprotected 
against secondary infections.64,111,115 Many other types of cells such as neurons, epithelial 
and endothelial cells, thymocytes, and cardiac myocytes also display accelerated 
apoptosis during systemic inflammation.111,116 Additionally, this increased level of 
apoptosis stimulates some of the remaining immune cells to secrete anti-inflammatory 
cytokines such as IL-10.113  
An overall increased production of IL-10 is characteristic of CARS.100,105,106 High levels 
of this cytokine are responsible for decreasing proinflammatory cytokine synthesis by 
Th1 cells, monocytes, neutrophils, and dendritic cells, as well as inhibiting monocytes of 
their ability to present antigens and activate cells of the acquired immune system.113,117–
122 Following systemic inflammation, there is also an increase in the number and 
suppression ability of regulatory T cells. These cells are a subpopulation of T cells that 
contribute to the development of CARS by reducing Th1 proliferation and inducing 
further apoptosis of monocytes and neutrophils.68,101,113,123 Interactions such as these 
encourage the shift towards a Th2 predominant response which results in the release of 
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additional IL-10 and other anti-inflammatory cytokines, further boosting 
immunosuppression.101,113 The CNS may also contribute to the development of CARS by 
inhibiting the release of proinflammatory cytokines by macrophages through the 
previously mentioned cholinergic anti-inflammatory pathway.91,92,101,109 Catecholamines 
and cortisol released as a result of the activation of the hypothalamic-pituitary-adrenal 
(HPA) axis, triggered by SIRS, also contribute to the shift towards Th2 predominance by 
inhibiting Th1 cytokine synthesis and upregulating Th2 cytokine production.88,106,113,124–
126 
Throughout the years, many theories have been made regarding the interactions between 
the hyperinflammatory and hypoinflammatory states observed in SIRS.102,103,127 Current 
models of SIRS suggest the occurrence of a cycle between each state with both 
contributing to patient morbidity and mortality.107,108,128 The development of secondary 
infections may be responsible for the generation of new proinflammatory responses and 
thus, the longer SIRS goes on, the more likely a patient is to experience profound 
immunosuppression.107 Regardless of which state is predominant, it appears that both 
proinflammatory and anti-inflammatory responses are concurrently active during the 
syndrome.107,108,127,128 
 
1.2.2.4. SEPTIC SHOCK 
Septic shock is the most severe form of sepsis.129,130 According to its most recent 
definition, septic shock is considered “a subset of sepsis in which underlying circulatory, 
cellular, and metabolic abnormalities are associated with a greater risk of mortality than 
sepsis alone”.25 As mentioned earlier, septic shock involves persistent hypotension and is 
characterised by the need for vasopressor therapy to maintain the minimum MAP levels 
of 65 mmHg, as well as the presence of a serum lactate level greater than 2 mmol/L, 
despite adequate fluid resuscitation.25 
The excessive release of cytokines during early stages of sepsis leads to vascular changes, 
such as peripheral vasodilation and increased permeability of capillaries, that promote 
loss of intravascular fluid, reduced systemic vascular resistance, and decreased venous 
return and preload. To maintain perfusion as a response to these hemodynamic changes, 
1. LITERATURE REVIEW 
14 
 
heart rate and stroke volume increase. This hemodynamic instability is what characterises 
the initial hyperdynamic phase of SIRS.51,81  
As the syndrome progresses, widespread microvascular thrombosis develops, further 
hindering blood flow and tissue oxygenation.81,131,132 Ultimately, this hemodynamic 
instability evolves into myocardial depression, followed by cardiovascular collapse, the 
establishment of the hypodynamic phase of SIRS, and the development of septic shock 
(Figure 3).51,133 Systemic oxygen delivery becomes insufficient to meet the demands of 
the tissues and generalised tissue hypoxia occurs, leading to the increased production of 
lactate due to anaerobic cellular respiration.134,135 The resulting tissue hypoxia is a 
consequence of generalised inflammation, and it may also further amplify the 
inflammatory response by inducing the production of additional proinflammatory 
cytokines.136 
Thus, septic shock is a complex type of shock that not only includes elements of 
distributive shock due to increased vascular permeability but also of hypovolemic and 
cardiogenic shock as a result of peripheral vasodilation and reduced cardiac output. 81 
 
 
 
  
 
 
  
 
 
Figure 3. The pathophysiology of septic shock (original figure). 
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1.2.2.5. THE MULTIPLE ORGAN DYSFUNCTION 
SYNDROME (MODS) 
The multiple organ dysfunction syndrome (MODS) is the ultimate sequela of SIRS and 
represents an increased risk of death.49,132,137 In fact, Kenney et al.138 have shown that the 
mortality rate of canine patients with sepsis suffers an increase for each additional 
dysfunctional organ system. MODS is characterised by the need of intervention to 
maintain homeostasis, which would be otherwise accomplished by adequate organ 
function.5 
When organ dysfunction is the outcome of a systemic inflammatory reaction, the resulting 
phenomenon is classified as secondary MODS for the reason that its development is a 
consequence of the host’s response to an insult. However, MODS can also be the direct 
result of the damage caused by the insult itself. In this case, the syndrome is identified as 
primary MODS, and it tends to unfold rather quickly.5 For example, a patient that has 
been hit by a moving vehicle may quickly develop acute lung injury as a result of 
traumatic pulmonary contusion. If this is not the case, the inflammatory reaction caused 
by the incident itself may become excessive and cause damage to the lungs, as well as to 
other organs.137 
The pathogenesis of secondary MODS is not entirely understood, but there appear to be 
many contributing factors to the development of organ failure.139,140 The hemodynamic 
changes resulting from the dysregulated inflammatory response in SIRS play a major role 
in the promotion of organ damage.82,137,140 Diminished tissue perfusion as a result of 
microvascular dysfunction and thrombosis leads to tissue hypoxia and cell death, which 
added to the increased apoptosis observed in SIRS, results in both organ damage and the 
release of additional DAMPs that perpetuate the inflammatory process.116,132,139,141,142 
Neutrophils that are recruited and activated during SIRS also contribute to the 
development of organ damage, not only by secreting additional inflammatory mediators 
that potentiate the inflammatory response but also by causing local tissue damage through 
the release of ROS and proteolytic enzymes.82,140,142 
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Mitochondrial dysfunction is considered to be highly involved in the pathogenesis of 
MODS.143,144 Generalised tissue hypoxia resulting from an exaggerated inflammatory 
response may compromise the mitochondrial function of generating adenosine 
triphosphate (ATP). Furthermore, the excessive amount of NO and ROS in circulation 
can cause direct damage to mitochondrial structures, such as the lipid membrane, and 
suppress mitochondrial respiration and ATP synthesis.145 Low levels of triiodothyronine 
(T3) resulting from thyroid dysfunction in critical illness are also believed to have an 
adverse impact on mitochondrial activity.145,146 Cell death occurs in the absence of ATP 
and with it the eventual alteration of organ function.144,145 Interestingly, the mitochondrial 
dysfunction caused by ROS seems to trigger the production of additional ROS by the 
mitochondria themselves, further amplifying the oxidative damage caused.147 
Additionally, damaging the mitochondria perpetuates the inflammatory response due to 
mitochondrial DNA being released and acting as a DAMP.84,148  
Clinical signs of dysfunction of the gastrointestinal tract (GIT) include changes in appetite 
such as hyporexia and anorexia, as well as vomiting, gastric ulceration, and 
diarrhoea.137,149 However, a dysfunctional GIT may also contribute to MODS through the 
phenomenon of bacterial translocation.150–152 Bacterial translocation is the passage of 
bacteria or antigenic macromolecules from the GIT to normally sterile tissues and organs, 
through the intestinal mucosal barrier.153,154 Reduced oxygen delivery to the GIT, once 
again as a result of the hemodynamic changes induced by SIRS, culminates in intestinal 
ischemia, epithelial cell injury and apoptosis, and increased intestinal permeability.155–157 
Additionally, hypoperfusion of the GIT results in reduced intestinal motility that 
promotes bacterial overgrowth.158,159 Furthermore, the absence of luminal nutrients due 
to undernutrition in critically ill patients further compromises the functional and structural 
integrity of the intestinal epithelium.156,160 Both the dysfunction of the intestinal barrier 
and bacterial overgrowth, as well as the presence of a dysfunctional immune system, 
favour bacterial translocation.152–155,161  
Early theories regarding bacterial translocation suggested that bacteria would reach the 
systemic circulation solely via the portal vein. However, this hypothesis was eventually 
rejected as new conflicting data emerged.162–164 It is currently believed that according to 
the “gut-lymph hypothesis”, the translocating bacteria and bacterial products are exposed 
1. LITERATURE REVIEW 
17 
 
to intestinal immune cells and stimulate the release of inflammatory mediators.151,157,164 
Although the majority of bacteria suffer phagocytosis and contribute to this local 
inflammatory response, a small number of translocated bacteria survive and become 
trapped in the intestinal lymph nodes, where additional inflammatory reactions are 
induced.161,165 Surviving bacteria, cell wall fragments and protein components of the dead 
bacteria, and cytokines and chemokines generated in the GIT then travel through the 
mesenteric lymphatics to the cisterna chyli and are released into systemic circulation via 
the thoracic duct. These products initially reach the pulmonary circulation and activate 
the alveolar macrophages. The end result of this process is the development of acute lung 
injury, along with the intensification of systemic proinflammatory activity and 
MODS.151,153 
Interestingly, the lungs are common targets of organ damage in patients with MODS.137 
Pulmonary damage as a result of a deleterious inflammatory response often leads to the 
development of acute lung injury, followed by its most severe presentation, the acute 
respiratory distress syndrome (ARDS).166 The process through which systemic 
inflammation promotes ARDS involves the infiltration of activated neutrophils into the 
pulmonary interstitium and alveolus, epithelial and endothelial cell damage and 
apoptosis, and increased microvascular permeability, followed by pulmonary oedema, 
atelectasis and interstitial fibrosis.111,139,140,167 Clinical signs of this pulmonary 
dysfunction may include respiratory distress, tachypnea, progressive hypoxemia, and 
cyanosis.166 
Dysfunction of the liver may also be observed in patients with MODS. Hepatic injury 
contributes to the establishment of hypoglycaemia as a result of reduced gluconeogenesis 
and glycogenolysis. Protein synthesis, along with lactate and amino acid clearance, also 
become decreased following hepatic dysfunction.168 Furthermore, activated Kupffer cells 
are responsible for producing a variety of inflammatory mediators that end up 
contributing to the local and systemic inflammatory responses.140,168 The main 
manifestations of hepatic dysfunction tend to be hyperbilirubinemia, as a result of 
intrahepatic cholestasis, and elevated levels of serum aminotransferases.137,168 
Cardiac dysfunction in MODS is often present in the form of myocardial depression.139 
The mechanism that leads to the development of myocardial depression is incompletely 
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understood and appears to be multifactorial.140,169 In addition to the previously mentioned 
harmful effects of systemic inflammation, cardiac dysfunction might be associated with 
alterations in calcium physiology, sympathetic overstimulation, and the presence of 
circulating myocardial depressant substances that are yet to be fully identified.137,169–171 
Manifestations of cardiac dysfunction may include hypotension despite fluid 
resuscitation, presence of arrhythmias, and tachycardia.137,140,169 Cats may also uniquely 
display bradycardia, which is thought to be the consequence of increased vagal tone or 
cytokine-associated myocardial depression.58 
The main phenomenon contributing to the development of acute kidney injury (AKI) and 
subsequent kidney dysfunction in MODS seems to be the increased epithelial cell 
apoptosis induced by inflammatory cytokines, whereas renal epithelium necrosis as a 
result of renal hypoperfusion appears to be less common.84,116,140 Not only does renal 
dysfunction promote an increase in serum creatinine concentration values but it may also 
contribute to the development of neurologic dysfunction.172 The process behind the 
dysfunction of the CNS is rather complex and involves the activation of cerebral 
endothelial cells and consequent alteration of the blood-brain barrier. The disruption of 
the blood-brain barrier causes the release of a variety of mediators into the brain that 
contributes to the activation of microglial cells, which are the local immune cells. These 
are then responsible for releasing proinflammatory mediators such as cytokines, NO, and 
ROS which cause local injury and perpetuate the dysfunction of the blood-brain barrier.173 
Encephalopathy and peripheral neuropathy are the repercussions of CNS damage in 
MODS, as well as the deterioration of the mental statuses of the affected patients.137,167 
Another sequela of SIRS is the occurrence of critical illness-related corticosteroid 
insufficiency (CIRCI) due to the dysfunction of the HPA axis and subsequent adrenal 
insufficiency.126,174–176 The HPA axis is activated in response to the stress caused by the 
systemic inflammatory insult.177 Activation of the HPA axis ultimately leads to increased 
cortisol release from the adrenal cortex.176 This increase in cortisol production is 
important in the organism’s adaptation to illness and the magnitude of its release tends to 
be proportional to the severity of stress.146,176,178 Cortisol contributes to the maintenance 
of adequate perfusion to the vital organs by aiding in the modulation of the immune 
response and in the preservation of vascular reactivity to circulating 
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catecholamines.135,146,176 However, this response weakens as SIRS progresses, resulting 
in reduced adrenal function and the establishment of CIRCI.126,179 CIRCI represents the 
inadequacy in corticosteroid activity for the severity of a patient’s illness, and it can be 
the result of adrenal failure or tissue resistance to corticosteroids.176,180,181 Even though 
CIRCI tends to disappear with the resolution of SIRS, it is possible that some patients 
develop long-term adrenal insufficiency due to structural damage to the adrenal glands as 
a result of haemorrhage and ischemia.146,180 CIRCI can lead to further hemodynamic 
instability along with persistent hypotension.41,146 
 
1.3. COAGULOPATHY IN SEPSIS 
Sepsis is associated with haemostatic abnormalities resulting from the dysfunctional 
activation of blood coagulation throughout the process of systemic inflammation.83,140,182 
The promotion of clotting observed in SIRS results in coagulation abnormalities that 
range from subclinical clot formation to widespread microvascular thrombosis and 
haemorrhage which are typical of disseminated intravascular coagulation (DIC).183,184 
The coagulation disorders that accompany sepsis are major contributors to the 
development of MODS and are thus associated with increased mortality.83,132,137,140,185 
The systemic inflammatory response present in SIRS is responsible for inducing 
dysfunctional coagulation through three primary mechanisms: increased activation of 
blood coagulation, impairment of anticoagulant mechanisms and suppression of 
fibrinolysis.128,182,185,186 
 
1.3.1. FROM SYSTEMIC INFLAMMATION TO THE 
ACTIVATION OF BLOOD COAGULATION 
Coagulation used to be traditionally described through a cascade model involving 
independent intrinsic and extrinsic pathways. At the present time, however, this 
classification is deemed outdated, and a newer cell-based model is considered to offer a 
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better description of the coagulation process. This contemporary model describes 
coagulation through three different phases: initiation, amplification, and propagation.187–
191  
Tissue factor (TF) is a 47 kDa transmembrane glycoprotein whose expression plays a 
central role in the activation of blood coagulation in sepsis.132,192 The disruption of 
vascular integrity caused by inflammation leads to the exposure of TF in cells which are 
not in circulation or direct contact with blood.186,193 Furthermore, cytokines released 
throughout the systemic inflammatory process, such as TNFα, IL-1, and IL-6, are 
responsible for inducing endothelial, immune, and various other cell types to express 
TF.132,186,194–196  
Once exposed to the bloodstream, TF binds to circulating coagulation factor VII (FVII), 
also known as proconvertin, converting it to its active form (FVIIa) and generating an 
active TF-FVIIa complex.191,193,197 This complex is then responsible for activating factor 
IX (FIX), also called Christmas factor, to FIXa, and factor X (FX), also known as Stuart-
Prower factor, to FXa.190,191,198 FIXa also further activates FX by interacting with factor 
VIII (FVIII), also named antihaemophilic factor A, in its active form (FVIIIa).191,197 In 
turn, FXa forms a complex with factor V (FV), or proaccelerin, in its active form (FVa). 
The formed complex is then responsible for inducing the cleaving of prothrombin to 
thrombin.189,191,193,197 The aforementioned process represents the initiation phase of 
coagulation.187,189–191 
FXa is capable of generating a small amount of thrombin by itself, which in turn is 
responsible for activating FV and FVIII and subsequently bolstering further thrombin 
production.190,191,199 Initially generated thrombin activates nearby platelets, which are 
essential in the amplification of the coagulation process.190,193,199,200 During the 
inflammatory response, exposed collagen as well as circulating endotoxin and 
proinflammatory mediators, such as platelet-activating factor, may also activate 
platelets.186,187,190,193,200,201 The activation of a platelet leads to the expression of P-selectin 
on its membrane. Similarly, activated endothelial cells also express P-selectin. P-selectin 
is a glycoprotein that mediates the adherence of platelets to endothelial cells and 
leukocytes, which helps to localise thrombus formation. Additionally, these interactions 
lead to further NF-kB activation and monocyte TF expression.186,189,193,201 Activated 
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platelets and endothelial cells also release a glycoprotein called von Willebrand factor 
(vWF) which enhances both platelet aggregation and adherence to the site of injury.77,189 
As the platelet aggregate grows, a temporary platelet plug is formed.191,200 Once this 
localised plug is established, the activated platelets augment thrombin generation by 
providing a procoagulant phospholipid surface on which thrombin can convert FV to FVa 
and FVIII,  which is initially bound to vWF, to FVIIIa.190,191,193,201 Calcium acts as a 
cofactor in many interactions throughout the coagulation process by facilitating 
coagulation factor assembly on phospholipid membranes, such as those of activated 
platelets.189,191,197,199,202,203 
The activation of platelets and generation of FVa and FVIIIa represent the amplification 
phase of the coagulation process, whereas the resulting increased thrombin generation 
represents the propagation phase (Figure 4).187,189–191  
 
 
Figure 4. The current concept of coagulation in sepsis (original figure). Tissue factor 
forms a complex with factor VIIa (FVIIa) that ultimately leads to the generation of trace 
amounts of thrombin. The generated thrombin then activates factor V (FV) and factor 
VIII (FVIII) on the membrane of activated platelets, which results in a substantial increase 
in thrombin production.190,191,197 
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The propagation phase results in the generation of a burst of thrombin that causes the 
conversion of fibrinogen to fibrin.187,189 Thrombin additionally activates factor XIII 
(FXIII), also known as fibrin-stabilising factor, whose function is to cross-link the fibrin 
now incorporated in the platelet plug, granting it enhanced strength and stability. 
Furthermore, thrombin activates the thrombin-activatable fibrinolysis inhibitor (TAFI), 
an enzyme that helps prevent the fibrinolysis of the newly formed thrombus.187,191 
 
1.3.2. IMPAIRMENT OF ANTICOAGULANT MECHANISMS 
Physiological anticoagulant pathways exist to prevent blood coagulation from becoming 
excessively activated. During systemic inflammation, however, these mechanisms may 
become suppressed. There are three main antithrombotic mechanisms through which 
procoagulant activity is regulated. These include the anticoagulant activity of the tissue 
factor pathway inhibitor (TFPI), protein C, and antithrombin (AT).73,188,193,204  
The majority of TFPI is bound to the microvascular endothelium. Smaller amounts of this 
glycoprotein can also be found in circulation, either bound to plasma lipoproteins or in 
free form, and within the cytoplasm of platelets.203,205–207 TFPI is released in response to 
thrombin and other stimulants. Interestingly, heparin is a potent inducer of TFPI 
release.205,207,208 TFPI inhibits the production of thrombin by binding to and inactivating 
FXa and the TF-FVIIa complex.83,207,209,210 In sepsis, the production of TF that 
accompanies the systemic inflammatory response appears to overwhelm the generation 
of TFPI, thus promoting a procoagulant state.132,206,211–213 Furthermore, an enzyme called 
neutrophil elastase, which is released by activated neutrophils during inflammation, is 
responsible for causing the proteolysis of TFPI, preventing it from inactivating FXa and 
the TF-FVIIa complex.212,214,215 Studies with animal models have shown that both the 
administration of TFPI and the inhibition of neutrophil elastase, in sepsis, were associated 
with improved survival.216,217 
Protein C is a circulating glycoprotein which is activated by thrombin. Once activated, 
protein C degrades FVa and FVIIIa, limiting further thrombin generation.189,191,193,203,218 
Additionally, thrombin complexes with a transmembrane receptor present on endothelial 
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cells named thrombomodulin. The creation of this complex enhances protein C activation 
which leads to a substantial increase in the generation of activated protein C 
(aPC).189,191,203,219 Protein C activation is further amplified by the presence of another 
receptor found on the membrane of endothelial cells, the endothelial protein C receptor 
(EPCR), that binds to it and optimally presents it to the complex formed between 
thrombin and thrombomodulin.193,203 The combination of protein C consumption and 
reduced production due to organ dysfunction, namely the dysfunction of the liver, where 
it is synthesised, is likely the reason why protein C levels become reduced in septic 
patients, contributing to the development of a procoagulant state and increased 
mortality.203,220–223 Protein S, another glycoprotein which acts as a cofactor to aPC in the 
inactivation of FVa and FVIIIa, may also contribute to the development of a procoagulant 
state by becoming reduced in a similar fashion.182,191,203,224 The anticoagulant capability 
of Protein S is not confined to its interaction with protein C, as it is also responsible for 
enhancing the interaction between TFPI and FXa and inhibiting the complex formed 
between FVa and FXa.191,203,225 Moreover, endotoxin, IL-1, and TNFα are all responsible 
for inhibiting the expression of thrombomodulin and EPCR.184,222,226–228 
Thrombomodulin activity is further impaired by neutrophil elastase which cleaves it from 
the endothelial cell membrane, generating a less active form of the receptor.184,185,222,228,229 
AT is another circulating glycoprotein with anticoagulant properties mainly due to its 
ability to bind to and inhibit thrombin, as well as other coagulation factors such as FIXa 
and FXa.191,222,230–232 The presence of heparin highly improves the inhibitory ability of 
AT. However, physiological circulating levels of heparin are not high enough to 
significantly contribute to the activation of AT.191,231,233 Thus, in the absence of heparin, 
AT is activated by endogenous glycosaminoglycans, such as heparan sulphate, expressed 
on the surface of endothelial cells.224,232–235  In sepsis, AT levels are considerably reduced 
due to its consumption caused by continued thrombin generation. Reduced synthesis and 
degradation by neutrophil elastase also contribute to the depletion of AT during severe 
inflammation.182,193,203,222,223 Furthermore, proinflammatory cytokines released during the 
inflammatory response suppress the production of glycosaminoglycans on the endothelial 
surface, subsequently impairing AT function.184,193,224,235 
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1.3.3. SUPPRESSION OF FIBRINOLYSIS 
Fibrinolysis exists as a parallel mechanism through which haemostasis is 
regulated.188,191,235,236 For fibrinolysis to occur, plasminogen must be converted to 
plasmin. Plasminogen is primarily synthesised in the liver and requires posterior 
activation to plasmin to perform its fibrinolytic function.203,236,237 Plasminogen is usually 
activated once incorporated into the clot, which is only possible due to its affinity for 
fibrin.203,238 Following its conversion, plasmin causes the proteolysis of fibrin, dissolving 
the fibrin clot into fibrin degradation products, which are cleared by the liver.191,238 Fibrin 
itself enhances plasminogen activation.190,239 
The main plasminogen activating enzymes include the tissue plasminogen activator 
(TPA) and the urokinase-type plasminogen activator (UPA).188,203,236,239 TPA is the most 
important plasminogen activator. It is synthesised by endothelial cells and released both 
constitutively and as a response to a variety of triggers including cell injury and thrombin 
stimulation.188,190,191,236,238,239 TPA requires the presence of fibrin to adequately activate 
plasminogen.190,239,240 In comparison, UPA appears to play a minor role in the conversion 
of plasminogen to plasmin. It can, however, be produced by a larger number of cells, 
including monocytes, endothelial cells, and epithelial cells, and is released in response to 
cell activation by endotoxin and inflammatory cytokines.241,242 Unlike TPA, UPA binds 
to specific cell surface receptors named urokinase-type plasminogen activator receptors 
(UPARs), and not fibrin, to activate plasminogen.203,236,240 
Fibrinolysis is limited by the activity of the previously mentioned TAFI and by 
plasminogen activator inhibitors (PAIs), both of which are suppressed by aPC. While 
TAFI reduces the rate of fibrinolysis by protecting fibrin from the breakdown caused by 
plasmin, PAIs prevent the activation of plasminogen by irreversibly inhibiting both TPA 
and UPA.191,203,204,235,243 The main PAI is the plasminogen activator inhibitor type 1 (PAI-
1), which is produced by a miscellany of cells including platelets, leukocytes, and 
endothelial cells.203,219,236,239  Fibrinolysis is further suppressed by circulating plasmin 
inhibitors, such as alpha-2-antiplasmin and alpha-2-macroglobulin.191,203,219,238 
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During sepsis, the elevated levels of TNFα and IL-1 in circulation cause an increased 
secretion of both TPA and UPA.132,193 The resulting rise in fibrinolytic activity is rapidly 
counteracted by a sustained release of PAI-1, strongly inhibiting fibrinolysis and 
contributing to a procoagulant environment.132,188,244  
 
1.3.4. ADDITIONAL INTERACTIONS BETWEEN 
INFLAMMATION AND COAGULATION 
Systemic inflammation contributes to the development of a procoagulant state in septic 
patients. The opposite, however, is also true, as blood coagulation further stimulates the 
inflammatory response.182,184 Procoagulant proteases such as TF, FVIIIa, FXa, and 
thrombin can activate protease-activated receptors (PARs), which are expressed by 
platelets, leukocytes, and epithelial and endothelial cells. PARs mediate cell activation, 
and thus, once activated themselves, these receptors can trigger the synthesis of 
inflammatory mediators that further enhance the inflammatory response.207,245–247  
The inhibition of physiological anticoagulant and fibrinolytic mechanisms further 
contributes to the progression of a proinflammatory environment since a large number of 
the anticoagulant enzymes involved in these processes also hold anti-inflammatory 
properties.184,243,247 For example, both aPC and TFPI appear to inhibit leukocyte 
activation and cytokine production. 184,210,248,249 
In addition to the presence of invading microorganisms and tissue damage, blood 
coagulation is also involved in the complex process that is the activation of the 
complement system. While initially helpful in the elimination of spreading 
microorganisms, the sustained activation of the complement system is, as previously 
mentioned, detrimental, by inducing further proinflammatory activity and thus 
contributing to the development of MODS.96,250 The activation of the complement system 
amplifies coagulation by inducing platelet activation and stimulating TF and PAI-1 
expression.251–253 Additionally, the complement system also inhibits the anticoagulant 
activity of protein S.225,254 In turn, thrombin can activate the complement system by 
cleaving two of its main proteins, complement component 3 (C3) and complement 
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component 5 (C5), into their activated form. Various other factors involved in the 
haemostatic process, including FXa, FXIIa, and plasmin, can also cleave and activate C3. 
The activation of these two complement components, however, can be suppressed by 
TAFI.77,253,255 
The involvement of factor XII (FXII), also known as Hageman factor, in the development 
of dysfunctional coagulation in sepsis is not fully understood. FXII was part of the old 
cascade model of the coagulation process as one of the initial factors of the intrinsic 
pathway.191,256,257 While the role of FXII in sepsis-induced coagulopathy appears to be 
secondary and controversial, it does seem that bacteria are capable of directly activating 
it.83,256–259 Interestingly, the activated form of this glycoprotein can activate the 
complement system by cleaving complement component 1 (C1), and the inhibition of this 
activation appears to reduce complement activity.77,257 
 
1.3.5. DISSEMINATED INTRAVASCULAR COAGULATION 
(DIC) IN SEPSIS 
While blood coagulation may start off as a beneficial process that allows the entrapment 
of bacteria and healing of wounds, it quickly becomes extremely harmful once 
excessively activated.132,204,260 DIC is the result of the combination of the previously 
described haemostatic abnormalities that occur during sepsis.  Severe trauma is another 
condition amongst critically ill patients which frequently develops an exaggerated 
inflammatory response that results in DIC, mostly due to the massive exposure of 
damaged tissue to the blood circulation.183,261,262 Trauma-induced DIC should not be 
confused with acute traumatic coagulopathy (ATC) which is a possible consequence of 
acute trauma, associated with increased fibrinolysis. The process of ATC development 
appears to be controversial and yet to be entirely understood.262–264  
The process through which coagulopathy occurs and causes organ dysfunction is nearly 
identical in both infectious and non-infectious causes of SIRS, and some previous studies 
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have even shown no significant differences in systemic cytokine patterns, platelet 
function, and clot formation amongst patients with sepsis and nonseptic SIRS.249,265,266  
Early DIC is associated with an hypercoagulable and prothrombotic state. As the 
condition progresses, however, a shift occurs towards hypocoagulability and 
haemorrhage. Ultimately, patients with DIC end up manifesting both widespread 
microvascular thrombosis and diffuse bleeding as a result of the continuous consumption 
and subsequent depletion of platelets and coagulation proteins, caused by the incessant 
activation of the coagulation system.132,265 While haemorrhage may lead to the 
development of anaemia and further loss of platelets and coagulation factors, thrombosis 
remains one of the main mechanisms leading to organ dysfunction.137,183,267,268  Hepatic 
dysfunction can further aggravate the occurring coagulopathy since the majority of 
coagulation factors are synthesised in the liver.137,191,269  
 
1.3.6. ABNORMAL COAGULATION TIMES IN SEPSIS 
The occurrence of coagulopathy in sepsis reproduces abnormal results when assessing 
coagulation function. The activated partial thromboplastin time (aPTT) test and the 
prothrombin time (PT) test are two of the most commonly used screening tests for 
coagulation abnormalities, including the ones observed in DIC.199,249,270 These tests are 
based on the evaluation of the integrity of the extrinsic and intrinsic pathways of the 
coagulation process, according to its cascade model. PT evaluates the integrity of the 
extrinsic pathway while aPTT verifies the state of its intrinsic counterpart. Both of these 
tests are also affected by abnormalities in the final common pathway.199,270 Despite the 
current cell-based model description of the coagulation system, these tests can be used to 
estimate the concentration of the different coagulation factors.271 The tests do not, 
however, indicate the cause of coagulation factor depletion.270 
The aPTT test represents the time it takes for a fibrin clot to be formed upon FXII 
activation, expressed in seconds.272 It evaluates deficiencies of the following factors: 
prothrombin, fibrinogen, FV, FVIII, FIX, FX, FXII, and factor XI (FXI), which is also 
known as plasma thromboplastin antecedent.261,270,272 The test consists of adding a 
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phospholipid platelet substitute, a FXII activator, and calcium to a plasma sample, 
generating the activation of the coagulation system.270,272 Similarly to the aPTT test, PT 
measures the time it takes for a clot to be formed in a plasma sample, following the 
addition of calcium and phospholipids with tissue factor.270,273 The PT test detects 
deficiencies of the following factors: prothrombin, fibrinogen, FV, FVII, and FX.261,270,273 
Both tests can be performed manually or with the use of automated devices.272,273 
Despite their utility, these tests are accompanied by some limitations. Variables such as 
prolonged storage, sample contamination, and inadequate sample volume all affect test 
results. Additionally, aPTT and PT tests do not provide information in regards to platelet 
function or fibrin clot stability. Furthermore, the reference values and sensitivity of aPTT 
and PT tests depend on the instrument and reagents used to perform the tests 
themselves.270,271,273 
The coagulation factor consumption observed in sepsis-induced DIC may lead to the 
prolongation of both aPTT and PT.261,271–273 The absence of abnormal results in any of 
these tests should not be enough reason to discard the presence of sepsis, since the 
prolongation of coagulation times may not be observed in all affected patients. However, 
it appears to be likely for septic patients to exhibit an elevated result in at least one of the 
two tests.140,183,261,274,275 For example, in their study regarding organ dysfunction in dogs 
with sepsis, Kenney et al.138 considered the presence of coagulation dysfunction once an 
increase of at least 25%, in either aPTT or PT, was observed. In this same study, 60.5% 
of the septic dog population met the criteria. In a different study by de Laforcade et al.57 
on haemostatic changes in dogs with naturally occurring sepsis, the same standards 
regarding aPTT and PT were used to identify DIC. In this study, however, only 25% of 
septic dogs fulfilled the criteria. 
Additionally, coagulation time prolongation may occur before clinical signs of inadequate 
haemostasis become apparent.271 Shortened coagulation times are, for the most part, 
considered to be of limited clinical significance.272,273 
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1.4. RECOMMENDED SCORING SYSTEMS FOR THE 
ASSESSMENT OF ORGAN DYSFUNCTION IN SEPSIS 
Many human organ function scoring systems have been developed to evaluate critically 
ill patients and guide therapy. However, a veterinary-specific MODS scoring system is 
yet to be created, and the application of human organ failure scores in veterinary patients 
is still subject of research.84,276  
As previously mentioned, the authors of Sepsis-3 proposed the use of the SOFA score for 
the assessment of organ dysfunction in septic patients.24 The SOFA score was created in 
1994 and is based on the evaluation of six organ systems: respiratory, hematologic, 
hepatic, cardiovascular, neurologic, and renal.277 SOFA was initially an acronym for 
“sepsis-related organ failure assessment” score but was later renamed due to its 
applicability to nonseptic patients.276 Each organ system is given a score, from zero to 
four points, according to how altered its function is. Mortality rates are expected to rise 
in correlation with the increase in score for each organ system. All six scores are then 
combined to generate the total SOFA score, which ranges from zero to 24 points.277,278 
The authors of Sepsis-3 considered a total SOFA score equal to or greater than two points 
to be representative of organ dysfunction in septic patients and reflective of an increased 
mortality risk of approximately 10%.24,26  
Even though the SOFA scoring system was created to be used in human patients, a study 
by Ripanti et al.279 with the goal of testing the applicability of the SOFA score in the 
assessment of outcome in critically ill dogs has shown promising results that support its 
use in such canine patients. This same study used slightly different values from the ones 
initially proposed for the criteria utilised by the SOFA scoring system when applied to 
human patients. Some authors have also advocated the use of the modified version of the 
Glasgow Coma Scale in the evaluation of neurologic function in veterinary patients, 
instead of its original version (Appendix A, p. ii).84,280–282 The adaptation of the SOFA 
score criteria to veterinary patients can be observed in Table 2. 
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Table 2. The sequential organ failure assessment (SOFA) score criteria for veterinary 
patients (adapted from references 84 and 279).  
 Score 
System 0 1 2 3 4 
Respiratory 
PaO2/FiO2 
(mmHg)A 
> 400 < 400 < 300 
< 200 
(Ventilated) 
< 100 
(Ventilated) 
Hematologic 
Platelets 
(103/mm3) 
≥ 150 ≤ 150 ≤ 100 ≤ 50 ≤ 20 
Hepatic 
Bilirubin (mg/dl) 
< 0.6 0.6 – 1.4 1.5 – 5.0 5.1 – 11.0 > 11.1 
Cardiovascular 
MAP B (mmHg) 
or vasopressors C 
≥ 60 < 60 
Dopamine < 5 or 
dobutamine (any 
dose) C 
Dopamine > 5 or 
epinephrine ≤ 0.1 
or norepinephrine 
≤ 1 C 
Dopamine > 15 or 
epinephrine > 0.1 
or norepinephrine 
> 1 C 
Neurologic 
Modified Glasgow 
Coma Scale 
> 14 13-14 10-12 6-9 <6 
Renal 
Creatinine (mg/dl) 
< 1.4 1.4 – 1.9 2.0 – 3.4 3.5 – 4.9 >5 
 
A PaO2/FiO2, Partial pressure of oxygen/fraction of inspired oxygen. 
B MAP, Mean arterial 
pressure. C Vasopressors are administered for a minimum of one hour. Doses given are in 
µg/kg/min. 
 
The SOFA scoring system is incredibly helpful in the identification of organ dysfunction, 
but it may become too time-consuming and impractical to apply, both outside the ICU 
and in smaller and less equipped veterinary centres, due to its complexity and the need 
for laboratory testing. Even though it may be performed retrospectively using criteria 
assessed in the past as part of routine screening, the SOFA score does not represent a tool 
of speedy results, which led to the creation of its simplified version: the qSOFA score.24–
26,36  
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The qSOFA score is a simple tool that allows the identification of patients with suspected 
infection, outside the ICU, who are at a higher risk of developing a poor outcome.24 The 
qSOFA score incorporates three criteria: increased respiratory rate, altered mentation, and 
low systolic blood pressure (Table 3). One point is awarded for the fulfilment of each 
criterion, up to a maximum of three points. A score of two or more points is considered 
to be predictive of prolonged ICU stay and in-hospital death and should prompt further 
examining.24,26,36 
 
Table 3. The quick sequential organ failure assessment (qSOFA) score criteria (adapted 
from reference 24).  
qSOFA Criteria 
Respiratory rate ≥ 22 breaths/min 
Modified Glasgow Coma Scale score < 15  
Systolic blood pressure ≤ 100 mmHg 
 
The qSOFA scoring system should not be used as a diagnostic tool for sepsis but rather 
as an early warning system that encourages clinicians to further evaluate patients with 
suspected infection for the presence of organ dysfunction, to initiate or adapt therapy, to 
increase the frequency of monitoring, and to consider a transfer to an ICU.24,36 Patients 
without suspected infection who display signs of qSOFA scores equal to or greater than 
two points should also be targets of increased surveillance and concern. Likewise, patients 
who are very likely to be infected despite having lower qSOFA scores should not be 
disregarded.36,40 
The predictive validity of the qSOFA score appears to be similar to that of the SOFA 
score outside the ICU. In an ICU setting, however, SOFA possesses greater prognostic 
accuracy, likely due to the influence of ongoing organ support through mechanical 
ventilation and vasopressor therapy.26,27 
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Although a tool of great utility, the qSOFA score is not flawless. It is possible for septic 
patients to score less than two points since other forms of organ dysfunction such as 
hematologic, renal, and hepatic dysfunction are not being evaluated when qSOFA is 
applied. The opposite may also occur when nonseptic patients are given high qSOFA 
scores even though the degree of their tachypnea, altered mental status or hypotension is 
not high enough to meet the SOFA criteria evaluated afterwards.36 Furthermore, it is 
possible that patients do not manifest the qSOFA criteria at all until late in the disease 
process when it might be too late for initiating treatment.29,40 Thus, organ function should 
not be evaluated exclusively through the use of scoring systems as these are not perfect. 
Clinical judgement and further testing should be applied if the clinician is still suspicious 
of the presence of sepsis even after examining patients with low SOFA or qSOFA scores 
(Figure 5).36,283 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. The identification process for sepsis and septic shock according to Sepsis-3 
(adapted from reference 24).
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2. STUDY – THE PROGNOSTIC VALUE 
OF ABNORMAL COAGULATION TIMES 
 
2.1. STUDY INTRODUCTION 
Coagulation dysfunction seems to be a common occurrence in critically ill patients with 
sepsis or at risk of entering a septic state. The analysis of how this dysfunction evolves 
and correlates to disease and injury severity could lead the way into creating an additional 
tool of prognosis for the critically ill veterinary patient. Additionally, the qSOFA scoring 
system can be very useful in veterinary medicine since it can be quickly applied to our 
patients. However, like most tools at our disposal, qSOFA is not perfect. Thus, the main 
idea behind this study was not only to test the effectiveness of coagulation markers in the 
prediction of outcome but also to analyse if they could serve as a tool to strengthen the 
information given to the clinician by the qSOFA score. 
 
2.2. OBJECTIVES 
The aim of this study was to investigate the use of aPTT and PT, at admission to the ICU, 
as biological markers of coagulation dysregulation in critically ill patients who are at risk 
of developing sepsis, as well as their correlation with disease severity and outcome. A 
secondary objective was to correlate aPTT and PT with the qSOFA scoring system at the 
moment of admission to the ICU and evaluate their combined use as a tool of prognostic 
value amongst critically ill patients.
2. STUDY – THE PROGNOSTIC VALUE OF ABNORMAL COAGULATION TIMES 
 
34 
 
2.3. MATERIALS AND METHODS 
2.3.1. STUDY POPULATION 
A total of 43 dogs were enrolled in the study between September 2016 and March 2017. 
Breeds included 17 mixed breeds, four Labrador Retrievers, two Bullmastiffs, two 
German Shepherds, two Pekingese, two Yorkshire Terriers, and one of each of the 
following: Beagle, Belgian Shepherd, Boxer, Bull Terrier, Chihuahua, Czechoslovakian 
Wolfdog, Dachshund, English Cocker Spaniel, German Shorthaired Pointer, Great Dane, 
Miniature Pinscher, Miniature Poodle, Pomeranian, and Portuguese Sheepdog. Twenty-
six of the patients were male (60.5%), and 17 were female (39.5%). The median age was 
six years (range, 0.2-16 years). Appendix B (see p. iii-vi) incorporates a table with all the 
collected information regarding the dog population enrolled in this study. 
 
2.3.2. STUDY DESIGN 
This study was conducted in a veterinary hospital setting. Every dog that was presented 
for consultation during the six-month period was evaluated for the presence of SIRS, 
sepsis or coagulopathy. Inclusion criteria were the presence of clinical signs of bleeding, 
coagulopathy, infection, shock or SIRS. Patients with polytrauma, organ dysfunction or 
neoplasia were also included. Dogs that died before blood collection or whose owners did 
not consent to this procedure were excluded from the study. Other species were also 
excluded. 
Variables recorded for each subject included: signalment (breed, age and sex), diagnosis, 
aPTT, PT, qSOFA score, and duration of hospitalisation and post-discharge treatment. 
Coagulation testing and qSOFA scoring were performed at the moment of admission to 
the ICU and continued to be applied and monitored throughout hospitalisation. All 
patients received specific treatment directed at their condition during hospitalisation. 
Those who survived hospitalisation continued receiving treatment at home administered 
by their owners and were re-evaluated on a weekly basis. 
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2.3.3. BLOOD SAMPLING AND COAGULATION TESTING 
Samples were collected for aPTT and PT determination from all dogs by atraumatic 
jugular venepuncture with sterile disposable syringes and needles (2 ml syringes and 20 
gauge needles). The puncture site was previously shaved and aseptically prepared with 
chlorhexidine gluconate 2% topical solution. A study by Bauer et al.284 suggests that 
different blood sample collection techniques do not alter coagulation testing results in 
dogs. A drop of the collected blood was then applied to a test strip (qLabs® Vet Coag 
Panel 2 Test Strip, Micropoint Bioscience inc., Santa Clara, USA) connected to a portable 
aPTT and PT analyser (qLabs® Vet Coag Panel 2 PT/APTT Combo, Micropoint 
Bioscience inc., Santa Clara, USA) (Figure 6). The portable device can detect the test 
strips on insertion and heat them up to a pre-set operating temperature while capillary 
channels transfer the blood to reaction zones to coagulate. The meter then detects the 
changes in these reaction areas and identifies a clot endpoint. These clot endpoints for 
both aPTT and PT testing are then converted to values which are more familiar to the 
clinician. The reference intervals of aPTT and PT for healthy dogs using the qLabs® test, 
stated by the manufacturer, are the following: an aPTT of 75 to 105 seconds and a PT of 
14 to 19 seconds. 
 
 
Figure 6. qLabs® Vet Coag Panel 2 device and test strips (original figure). 
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2.3.4. STATISTICAL ANALYSIS  
Excel software (Microsoft Corporation, Redmond, Washington, USA) was used for data 
management, and SPSS software (IBM, Armonk, New York, USA) was used to analyse 
data statistically. Chi-square tests were used to test independence between two categorical 
variables. T-tests were conducted to evaluate differences between two continuous 
variables. One-way analysis of variance (ANOVA) tests were performed to determine the 
existence of any differences between the means of more than two unrelated groups. 
Tukey’s honestly significant difference (HSD) tests were used to follow-up statistically 
significant ANOVA results. Pearson product-moment correlation coefficient tests were 
conducted to measure the association between two variables. For this statistical analysis, 
each qSOFA score (0, 1, 2, and 3) was considered a categorical variable. All relevant or 
statistically significant relations resulting from this analysis can be found in the following 
results. 
 
2.4. RESULTS 
2.4.1. DIAGNOSIS 
Fifteen of the 43 subjects died during treatment, which represented an overall mortality 
rate of 34.9%. Two dogs were euthanised due to the deterioration of their clinical 
condition, and the remaining 13 died spontaneously. Underlying causes of disease or 
injury were diagnosed on admission, such as trauma (n=10), neoplasia (n=9), 
gastrointestinal disease (n=8), toxicological emergency (n=4), urinary tract disease (n=4), 
infectious disease (n=3), neurological disorder (n=2), autoimmune disease (n=1), prostate 
disease (n=1), and respiratory disease (n=1).  Figure 7 shows the survival and non-
survival rates of each of these diagnoses. Neoplasia was the most common cause of death 
(33.3%), followed by trauma (26.7%), and urinary tract disease (13.3%). Despite a large 
number of subjects diagnosed with a gastrointestinal disease, only one of them 
succumbed to its illness. 
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Figure 7. Bar graph representing survival and non-survival rates of each of the diagnosed 
underlying causes of illness or injury. 
 
2.4.2. BREED, AGE, AND SEX 
The patients were divided into two groups in order for the relationship between their breed 
and outcome to be analysed: purebred and mixed breed patients. Six out of 17 mixed 
breed patients died during treatment which represents a mortality rate of 35.3% for this 
group. A nearly identical mortality rate of 35% was seen amongst purebred patients, 
having nine out of 26 patients died during treatment. No statistically significant 
relationship was found between breed and outcome. 
The average patient age in this study was 6.3 years. Survivors had a mean age of 5.7 years 
and non-survivors had a mean age of 7.5 years. No statistically significant relationship 
was found between age and outcome, but the results suggest that survivors were more 
inclined to be younger than non-surviving patients. 
A chi-square test of independence was performed to examine the association between sex 
and mortality, and no significant relationship between these two variables was found. 
However, females had a noticeably higher mortality rate (41.2%) than males (30.8%). 
Figure 8 shows the number of survivors and non-survivors of each sex. 
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Figure 8. Bar graph representing the number of survivors and non-survivors of each 
sex. 
  
2.4.3. qSOFA, ACTIVATED PARTIAL THROMBOPLASTIN 
TIME, AND PROTHROMBIN TIME 
The qSOFA scoring system was applied on admission to identify 10 patients with a score 
of zero points, 13 patients with a score of one point, 17 patients with a score of two points, 
and three patients with a score of three points. Eight of the 15 (53.3%) dogs that died 
during treatment scored two points on admission. Dogs with a score of three points had 
the highest mortality rate (66.7%). Table 4 shows the mortality rate associated with each 
score. A chi-square test of independence was performed once more, and no significant 
relation was found between qSOFA scores and mortality. However, the number of non-
survivors increased as qSOFA scores got higher, despite a similar number of survivors 
associated with each of the first three scores.  
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Table 4. The mortality rate associated with each quick sequential organ failure 
assessment (qSOFA) score in the present study. 
qSOFA score No. of patients No. of survivors No. of non-survivors Mortality 
0 10 9 1 10% 
1 13 9 4 30.8% 
2 17 9 8 47.1% 
3 3 1 2 66.7% 
 
A one-way ANOVA test was conducted to compare the effect of qSOFA scores on aPTT 
levels. There was a statistically significant difference between groups [F(3,39) = 3.420, 
p= 0.026]. A Tukey post hoc test revealed that aPTT values were significantly higher in 
patients with a qSOFA score of 2 points (121.5 ± 14.1, p = 0.029) compared to patients 
with a qSOFA score of 1 point (110.4 ± 7.9). There was no statistically significant 
difference between the other qSOFA scores. Mean aPTT values associated with each 
qSOFA score can be observed in Figure 9. A similar analysis was made for PT levels, but 
no statistically significant results were found.  
 
 
Figure 9. Graphical representation of mean activated partial thromboplastin time (aPTT) 
values associated with each quick sequential organ failure assessment (qSOFA) score. 
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A Pearson product-moment correlation test was run to determine the relation between 
aPTT and PT. There was a positive correlation between aPTT and PT which was 
statistically significant (r = 0.406, n = 43, p = 0.005). Figure 10 shows this correlation. 
  
 
Figure 10. Scatter graph representing the positive correlation between activated partial 
thromboplastin time (aPTT) and prothrombin time (PT). 
 
Regarding outcome, mean values for aPTT and PT were very similar between surviving 
and non-surviving patients. Surviving patients presented a mean aPTT value of 115.0 ± 
11.7 seconds and PT value of 16.8 ± 5.8 seconds. Non-survivors showed a mean aPTT 
value of 116.0 ± 10.7 seconds and PT value of 16.1 ± 3.5 seconds. 
 
2.4.4. LENGTH OF TREATMENT AND OUTCOME 
Ten of the 15 (66.7%) patients that died did so between their first and fifth day of 
hospitalisation and overall treatment. The other five deaths occurred while the patients 
were being treated at home, after having survived hospitalisation. Three of these five 
deaths (60%) were caused by neoplastic disease. The mean number of days of 
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hospitalisation and treatment associated with each outcome is represented in Table 5, 
which demonstrates how most deaths occurred early in treatment. 
 
Table 5. Mean length of hospitalisation and treatment of survivors and non-survivors.  
 
 
Mean length of hospital 
stay (days) 
Mean length of post-
discharge treatment (days) 
Total mean length of 
treatment (days) 
Survivors 6.39 ± 7.20 19.00 ± 17.57 25.40 ± 19.08 
Non-survivors 5.47 ± 6.42 10.20 ± 20.84 15.67 ± 22.50 
 
 
2.5. DISCUSSION 
The results of this study show a shortage of statistically significant relationships between 
the examined variables. However, there are a few statistically relevant relationships and 
other interesting findings that are worth considering. 
Based on the analysis of the different diagnoses made on admission, it is evident that 
trauma and neoplasia represented the most common reasons for hospitalisation as well as 
the leading causes of death. These are also amongst the most common causes of SIRS 
found in veterinary literature.44 It is important to mention that the diagnoses made in this 
study were secondary to its main objective and that patients were included by simply 
meeting the inclusion criteria. Therefore, it is possible that different underlying causes of 
hospitalisation were partly or entirely responsible for fluctuations in aPTT and PT values 
and outcome, regardless of qSOFA score or septic status. It is understandable that higher 
mortality rates in cases of neoplasia or more exuberant coagulation dysfunction in 
toxicological emergencies, such as the ingestion of anticoagulant rodenticides (which is 
the case of patient number seven, who presented the highest aPTT and PT values on 
admission), are clear examples of how disease pathophysiology can influence these 
results.285 The fact that very distinct aetiologies were included together, while each being 
represented by a small number of subjects, was also the reason why it was impossible to 
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search for any statistically significant relationships between diagnosis and other variables. 
The inclusion of patients with very diverse diagnoses is an evident flaw in this study, and 
it would be interesting for future studies on this subject to proceed with similar 
investigations for each particular disease or injury. 
It was interesting to find that both purebred and mixed breed patients had very similar 
mortality rates. However, each breed had a very minimal number of representatives, so 
additional studies with more subjects would be required for any conclusions to be drawn 
regarding breed-related susceptibility to sepsis. A study by Nemzek et al.286 suggests that 
breed affects cytokine production in dogs and consequently influences the host response 
to infection. Thus, more studies targeting this breed-related response would be interesting 
to develop.  
Even though no statistically significant relations were found in the analysis of patient age, 
the results suggest that older patients might be more affected by sepsis than younger ones. 
The results of a study performed by Antonelli et al.287 in human trauma patients also 
revealed that survivors were much younger than non-survivors. Additionally, a human 
medicine study carried out by Starr et al.288 showed that the adipose tissue of aged mice 
had an increased inflammatory potential when compared to that of young mice, which 
suggests that adipose tissue might be involved in the mortality of older patients. In another 
human medicine study by Walsh et al.289 regarding the outcome of critically ill patients 
with increased prothrombin time, it was found that patients with prolonged PT were not 
only more likely to be older but also to be female and suffering from sepsis. Regarding 
the impact of sex in this study, females displayed a higher mortality rate than males, but 
there was no statistically significant relationship between sex and outcome amongst the 
results. It was suggested in a human medicine study by Schreiber et al.290 that 
hypercoagulability following trauma is more common amongst females and is associated 
with increased mortality. Interestingly, three out of four females (75%) died following 
trauma in this study, whereas only one out of six males (16.7%) died in the same 
circumstances. 
The qSOFA scoring system was not only applied in this study because of its quick and 
straightforward nature but also because an aim of this study was to test if combining 
qSOFA with coagulation markers would be beneficial in the prediction of mortality in 
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critically ill patients, similarly to what has been investigated before in human and 
veterinary patients regarding plasma lactate concentration.291,292 The obtained results 
concerning qSOFA scores show that the majority of patients who died were scored with 
two points. Interestingly, the number of surviving subjects with a score of zero, one, and 
two points was the same, yet more deaths were observed as these scores increased. 
Patients with a score of three points had the highest mortality rate and were part of the 
only score with fewer survivors than non-survivors. However, it should be taken into 
consideration that this particular score was only represented by three subjects, which 
certainly affects the reliability of these results. Regardless, these results suggest that 
higher qSOFA scores tend to be associated with increased mortality rates. Therefore, the 
results of the present study are not only in agreement with the authors of the latest sepsis 
definition but also with a variety of human studies that revealed an increase in mortality 
as more qSOFA criteria were met.24,26,27,292–295 
A statistically significant relationship was found between qSOFA scores and aPTT 
values, which suggests that patients with a qSOFA score of two points tend to have higher 
aPTT values than the ones with lower scores. These results seem to insinuate that 
coagulation dysfunction gets considerably more severe as patients progress from a 
qSOFA score of one point to a score of two points, which makes sense given how 
mortality also appears to increase in patients with a score of two or more points, as 
previously mentioned. It would have been beneficial for this study to have additional 
patients with a qSOFA score of three points, not only to tackle the issue presented 
previously regarding mortality amongst patients with such score but also to properly 
analyse if these patients would have higher aPTT values than the ones with a score of two 
points.  
A study on haemostatic changes in dogs with naturally occurring sepsis by Laforcade et 
al.57 showed that dogs with sepsis tend to have higher aPTT and PT values when 
compared to controls, within 24 hours of admission, which is in line with the results of 
the present study if we consider a qSOFA score of two points to be highly indicative of 
sepsis. A different study by Ok et al.296 also reported an increase in aPTT and PT in dogs 
with sepsis when compared to healthy dogs. Contrary to what was seen regarding aPTT 
values, no relationship was found between qSOFA scores and PT values. These findings 
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seem to suggest the possibility of a relationship between aPTT values at admission and 
mortality. These results are also suggestive of a weaker or non-existent link between PT 
values at admission and mortality, which would be in agreement with other studies that 
have found only prolonged aPTT to be indicative of outcome. A previous study by 
Holowaychuk et al.297 showed that increased aPTT at hospital admission in dogs with 
severe traumatic injuries was correlated with injury severity and was also predictive of 
mortality. In this same study, however, PT was not predictive of outcome. A retrospective 
study by Bentley et al.60 had similar results by analysing two populations of dogs with 
septic peritonitis. In this study, aPTT was significantly prolonged amongst non-survivors, 
but PT was not significantly altered. Shipov et al.298 also found increased aPTT to be 
highly indicative of worse outcomes in cases of canine monocytic ehrlichiosis. Even 
though PT was prolonged in some dogs enrolled in this study, only aPTT was significantly 
prolonged upon presentation amongst non-survivors. Additionally, a study by Dengate et 
al.299 revealed the presence of increased aPTT, but not PT, in dogs with thrombosis 
secondary to underlying illnesses, when compared to healthy controls. 
The correlation between aPTT and PT was tested, and it does seem that when one 
increases, the other tends to do so as well. Despite the previous results, no statistically 
significant relationship was found between isolated aPTT or PT values and outcome, and 
both survivors and non-survivors had similar mean results for these two variables, which 
might indicate that aPTT and PT levels by themselves might not be the best tools for the 
prediction of outcome. These results are similar to those of a study by Bentley et al.300, 
which concluded that aPTT and PT were not useful in predicting mortality in dogs with 
septic peritonitis. In this same study, however, aPTT was still higher amongst non-
survivors, which is in line with what was previously mentioned. Adamantos et al.301 also 
found that abnormal aPTT and PT values were not correlated with outcome in a 
population of dogs who showed signs of bleeding and were infected with Angiostrongylus 
vasorum.  
Other authors, however, have had distinct results regarding coagulopathy at admission 
and outcome. In a study by Dhainaut et al.302, the results indicated that the presence of 
coagulation abnormalities in human patients during the first day of sepsis was predictive 
of either new organ dysfunction or progression and delayed resolution of already existing 
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organ dysfunction and consequently increased mortality rate. In a retrospective human 
study by Benediktsson et al.303, ICU admission values of aPTT and PT in patients with 
severe sepsis or septic shock were associated with outcome. In a study regarding cats with 
DIC by Estrin et al.304, the authors observed that aPTT was prolonged in all the cats 
affected by the disease. In this same study, PT was also prolonged in a significant number 
of cats with DIC, and the median PT of the non-surviving cats was significantly more 
prolonged than that of those who survived the disease. A study regarding heat stroke in 
dogs by Bruchim et al.305 found early changes in PT and aPTT to be significantly 
associated with mortality. Likewise, a distinct study on the same subject of heat stroke by 
Bruchim et al.306 also revealed the presence of longer aPTT and PT amongst non-
surviving dogs, in comparison to those who survived the illness. A study by Gottlieb et 
al.307, regarding trauma in dogs and cats, revealed that prolongation of both PT and aPTT 
was significantly related to injury severity in dogs. Other human studies concerning the 
subject of trauma also reported higher mortality rates amongst patients suffering from 
coagulopathy.308,309 In a human study by Adamik et al.310, the presence of coagulation 
disorders in septic patients, identified by thromboelastometry, was associated with higher 
mortality rates and increased endotoxin activity. Curiously, a study by Bauer & Moritz311 
showed that prolonged coagulation times and severe coagulopathy could be found in 
critically ill dogs, despite the presence of SIRS. 
Finally, results showed that most deaths occurred between the first and fifth day of 
treatment and that after that period the majority of patients survived. This information 
suggests that the first five days of treatment are the most complicated and decisive in 
critically ill patients, and allows the clinician to properly inform and guide the owners of 
patients going through similar circumstances, regarding their hospitalisation. Similar 
results in human patients with sepsis have been reported previously by Blanco et al.312. 
In this study, a quarter of the non-surviving patients died within the first 48 hours of 
admission to the ICU, and more than half died within the first week. 
This study was performed in a student internship setting at a veterinary hospital. Thus, 
the budget for the study was limited, and some patients could not be included due to the 
lack of consent by some of the owners and due to missing information amongst patient 
files. Individual treatment was also not considered since patients were suffering from 
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various diseases and injuries that required different medical intervention. The lack of a 
treatment protocol due to the volatile nature of the practice and diversity of diagnoses 
could have also influenced the results of this study.  
Once more, the author suggests that further studies regarding this subject should seek to 
investigate sepsis and coagulation dysfunction in patients with specific underlying 
diseases in a controlled environment and with the implementation of standardised 
treatment plans for each disease, as well as with a larger amount of subjects. 
 
2.6. CONCLUSIONS 
Sepsis is a severe and complex condition amongst critically ill patients which can lead to 
organ dysfunction and ultimately death if proper treatment is not applied in a timely 
fashion. Patients affected by this condition may also suffer from altered blood coagulation 
and are at risk of developing a disseminated intravascular coagulation state. 
Conclusions regarding the prognostic ability of aPTT and PT appear to be conflicting 
amongst different studies. The results of this study suggest that the assessment of aPTT 
and PT by itself, at admission to the ICU, may not be the most reliable way to form 
conclusions about the prognosis of critically ill veterinary patients. Contrary to these 
results, a variety of previous studies have found prolonged coagulation times upon 
presentation to be associated with outcome in critically ill patients.  
However, aPTT was significantly increased in patients with a qSOFA score of two points 
in the present study, which in turn is associated with increased mortality. These results 
may indicate that pairing coagulation time data, namely aPTT, with the qSOFA score, at 
the moment of admission to the ICU, might be a more reliable way to predict the outcome 
of critically ill patients. These results also suggest that even though the qSOFA score does 
not directly evaluate haemostatic dysfunction, it is likely for patients with a score of two 
points to be affected by some degree of coagulopathy.  
This study also shows that the first five days of treatment are the most crucial amongst 
the critically ill. This information is extremely useful not only in the clinician’s decision-
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making process but also as a way to supply the owners of critically ill patients with a risk 
time frame based on evidence. Based on these results, rash decisions regarding euthanasia 
should be reconsidered as most patients that survive the first five days of treatment tend 
to recover from their illnesses. Owners of critically ill patients should be given a time 
frame of at least five days of treatment for their dog, at admission to the ICU. Having 
such a survival based time frame to present to owners of critically ill patients represents 
an immensely helpful and practical tool to any veterinary clinician. Despite not being part 
of the proposed goals for this study, these achieved results regarding patient survival have 
been considered to be tremendously important by the author. 
There is still much to know about sepsis, and tools for its early detection should be further 
developed. At the present moment, the qSOFA scoring system seems to be a practical 
tool to use in veterinary medicine to assess risk amongst critically ill patients, but it should 
not be used as a singular diagnostic method. The SOFA score continues to be the thorough 
version of this tool for the recognition of organ dysfunction and sepsis between patients 
inside the intensive care unit, but its complex nature and need for laboratory testing might 
render it impracticable in a significant number of veterinary medical facilities. 
Further studies should be encouraged on this subject, both in human and veterinary 
medicine, so that in the future sepsis can be tackled more comfortably by clinicians in 
both fields. 
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Score category MGCS score Suggested prognosis 
I 3 to 8 Grave 
II 9 to 14 Guarded 
III 15 to 18 Good 
Modified Glasgow Coma Scale (MGCS) 
 Score 
Motor activity  
Normal gait, normal spinal reflexes 6 
Hemiparesis, tetraparesis, or decerebrate activity 5 
Recumbent, intermittent extensor rigidity 4 
Recumbent, constant extensor rigidity 3 
Recumbent, constant extensor rigidity with opisthotonos 2 
Recumbent, hypotonia of muscles, depressed or absent spinal reflexes 1 
  
Brain stem reflexes  
Normal pupillary light reflexes and physiological nystagmus 6 
Slow pupillary light reflexes and normal to reduced physiological nystagmus 5 
Bilateral unresponsive miosis with normal to reduced physiological nystagmus 4 
Pinpoint pupils with reduced to absent physiological nystagmus 3 
Unilateral, unresponsive mydriasis with reduced to absent physiological nystagmus 2 
Bilateral, unresponsive mydriasis with reduced to absent physiological nystagmus 1 
  
Level of consciousness  
Occasional periods of alertness and responsive to the environment 6 
Depression or delirium, capable of responding but response may be inappropriate 5 
Semicomatose, responsive to visual stimuli 4 
Semicomatose, responsive to auditory stimuli 3 
Semicomatose, responsive only to repeated noxious stimuli 2 
Comatose, unresponsive to repeated noxious stimuli 1 
APPENDIX A 
Modified Glasgow Coma Scale. (Adapted from references 280 and 281) 
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Patient 
ID 
 
Breed 
Age  
(y) 
 
Sex 
 
Diagnosis 
 
qSOFA 
score 
 
aPTT 
 
PT 
Length of  
hospital 
stay (d) 
Length of  
post-discharge 
treatment (d) 
Total length of 
treatment (d) 
 
Outcome 
1 Labrador Retriever 1 Female Gastrointestinal Disease 2 122,7 20,7 18 47 65 Survived 
2 German Shepherd 0,25 Male Gastrointestinal Disease 2 108,6 13,1 15 11 26 Survived 
3 Mixed Breed 3 Male Infectious Disease 0 119,9 16,3 35 0 35 Survived 
4 Mixed Breed 16 Female Neoplasia 0 116,6 16,3 5 0 5 Survived 
5 Mixed Breed 6 Male Gastrointestinal Disease 3 110,3 16,9 5 18 23 Survived 
6 Mixed Breed 2 Male 
Toxicological 
Emergency 
2 110,3 15 3 5 8 Survived 
7 Labrador Retriever 1 Male 
Toxicological 
Emergency 
2 143,6 44,3 8 73 81 Survived 
8 German Shorthaired Pointer 0,2 Male 
Toxicological 
Emergency 
1 114,9 14,9 3 0 3 Survived 
9 Bullmastiff 2 Male Gastrointestinal Disease 2 128,6 15,3 10 36 46 Survived 
10 Mixed Breed 6 Male Trauma 1 115 16,9 6 24 30 Survived 
APPENDIX B  
Dog population enrolled in the study. 
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11 Chihuahua 5 Female Neurological Disorder 2 122,4 19,5 8 19 27 Survived 
12 Mixed Breed 1 Female Trauma 1 107,8 15,2 2 0 2 Survived 
13 Pomeranian 10 Male Neoplasia 0 119,2 14,6 1 8 9 Survived 
14 Mixed Breed 9 Male Prostate Disease 0 111 13,6 1 38 39 Survived 
15 Belgian Shepherd 6 Male Trauma 0 108,4 15,2 4 10 14 Survived 
16 Boxer 9 Female Infectious Disease 0 102,3 13,8 3 2 5 Survived 
17 English Cocker Spaniel 9 Female Neoplasia 0 110,3 11,9 2 10 12 Survived 
18 Yorkshire Terrier 3 Male Trauma 2 142,3 18,9 4 38 42 Survived 
19 Yorkshire Terrier 15 Male Trauma 1 96 13,9 2 12 14 Survived 
20 Mixed Breed 5 Female Gastrointestinal Disease 1 113,3 14,6 1 34 35 Survived 
21 Mixed Breed 5 Female Gastrointestinal Disease 1 106,6 15,3 1 23 24 Survived 
22 Mixed Breed 6 Male Trauma 1 109,9 15,1 3 7 10 Survived 
 v 
 
23 Mixed Breed 15 Male Neoplasia 0 108,8 14,5 10 0 10 Survived 
24 Portuguese Sheepdog 8 Female Gastrointestinal Disease 2 105,8 18 7 19 26 Survived 
25 Beagle 4 Male Urinary Tract Disease 0 108 15,5 3 7 10 Survived 
26 Labrador Retriever 2 Male Respiratory Disease 1 111,9 16,8 14 30 44 Survived 
27 Pekingese 3 Female 
Toxicological 
Emergency 
1 105 15,6 1 31 32 Survived 
28 Dachshund 6 Male Urinary Tract Disease 2 141 18 4 30 34 Survived 
29 Labrador Retriever 13 Male Neoplasia 3 114,2 17,2 9 9 18 Died 
30 Czechoslovakian Wolfdog 1 Male Gastrointestinal Disease 1 105,5 16,9 8 46 54 Died 
31 Mixed Breed 11 Female Infectious Disease 2 121,4 18,3 21 9 30 Died 
32 German Shepherd 6 Male Urinary Tract Disease 1 124,7 16 4 0 4 Died 
33 Mixed Breed 12 Male Neoplasia 2 143,9 8,2 1 0 1 Died 
 vi 
 
34 Miniature Poodle 7 Female Trauma 2 110,5 12,9 2 0 2 Died 
35 Great Dane 9 Male Neoplasia 0 113,2 15,6 1 71 72 Died* 
36 Mixed Breed 1 Female Trauma 3 117 24,5 1 0 1 Died 
37 Mixed Breed 11 Female Neoplasia 1 122,3 15,1 19 18 37 Died 
38 Miniature Pinscher 6 Female Trauma 1 102 13 2 0 2 Died 
39 Bull Terrier 7 Female Autoimmune Disease 2 120 16,7 4 0 4 Died 
40 Pekingese 12 Male Neurological Disorder 2 105,9 18 1 0 1 Died 
41 Mixed Breed 8 Female Neoplasia 2 124 17,3 5 0 5 Died 
42 Bullmastiff 4 Male Urinary Tract Disease 2 104,5 15,1 3 0 3 Died* 
43 Mixed Breed 5 Male Trauma 2 110,8 16,3 1 0 1 Died 
 
Abbreviations: y, years; qSOFA, quick sequential organ failure assessment; d, days; aPTT, activated partial thromboplastin time; PT, 
prothrombin time.  
* = euthanised. 
